Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours

@article{Anderson2021UpdatesFT,
  title={Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours},
  author={William J Anderson and Leona A Doyle},
  journal={Histopathology},
  year={2021},
  volume={78},
  pages={644 - 657}
}
The fifth edition of the World Health Organization (WHO) classification of soft tissue and bone tumours was published in May 2020. This ‘Blue Book’, which is also available digitally for the first time, incorporates an array of new information on these tumours, amassed in the 7 years since the previous edition. Major advances in molecular characterisation have driven further refinements in classification and the development of ancillary diagnostic tests, and have improved our understanding of… 
‘I Can’t Keep Up!’: an update on advances in soft tissue pathology occurring after the publication of the 2020 World Health Organization classification of soft tissue and bone tumours
TLDR
This review will attempt to summarise the developments in soft tissue pathology that have occurred since 2020, emphasising lesions for which morphology and genetics intersect in a complementary fashion.
What’s new in adipocytic neoplasia?
TLDR
This review summarises the new developments in benign and malignant adipocytic neoplasms, with discussion of new entities and genetic findings, updates on the clinical and morphological spectrum, and the use of diagnostic immunohistochemistry and molecular markers in the differential diagnosis.
Natural History and Treatment Strategies of Advanced PEComas: A Systematic Review
TLDR
Based on clinical data collected from 124 case reports, metastatic disease at diagnosis and a grouped version of the Bleeker’s risk category were the only factors significantly associated with death.
Primary Alveolar Soft Part Sarcoma of Cheek: Report of a Case and Review of the Literature
TLDR
This tumour was a well-circumscribed, smooth, round mass that was clinically suspected as a benign tumour, however, histologically, it was observed that the polygonal tumour cells were arranged in solid and alveolar growth patterns.
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
TLDR
This review provides scientific answers to clinical phenomena and occasionally defines the resulting translational studies needed to overcome the hurdle of treatment-associated morbidities and, most importantly, non-survival in patients with Ewing sarcoma.
Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas
TLDR
The positive experience of two Spanish hospitals in the use of genomic analysis in the overall clinical management of sarcomas in children and young adults is presented and on a case-by-case basis how genomic analysis has contributed to both diagnosis and treatment is described.
Retroperitoneal Liposarcoma: A Case Report and Review of Literature
TLDR
A patient diagnosed with a retroperitoneal liposarcoma is reported to have been treated with primary radical surgery and is currently being followed-up in the authors' unit with close monitoring and Computed Tomographic (CT) imaging.
Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice
TLDR
The advancement in technologies for capturing and enumerating all diverse CTCs phenotype originating from these mesenchymal tumors are presented, and results provide a promising basis for clinical application of CTC detection in sarcoma.
Does PAX7 and NKX2.2 immunoreactivity in Ewing sarcoma have prognostic significance?
TLDR
IHC for CD99, NKX2.2, and PAX7 may be useful in daily practice for ES diagnosis, particularly in hospitals lacking facilities for molecular studies, and the combination of strong CD99 membranous positivity and nuclear PAX7 and NKX 2.2 immunoreactivity seems to be very reliable forES diagnosis when supported by a corroborating histomorphologic and clinical picture.
Chondrosarcoma of the Temporomandibular Joint: Systematic Review and Survival Analysis of Cases Reported to Date
TLDR
The purpose of this systematic review was to summarize the available data on TMJ chondrosarcomas and to perform a survival analysis of cases reported to date, and Synovial subtype, absence of reconstructive surgery, and presence of local recurrence or distant metastasis were associated with poorer prognosis.
...
1
2
3
...

References

SHOWING 1-10 OF 109 REFERENCES
Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone.
  • V. Jo, L. Doyle
  • Medicine
    Surgical oncology clinics of North America
  • 2016
TLDR
The fourth edition of the World Health Organization (WHO) Classification of Tumours of Soft Tissue and Bone was published in February 2013 and provides an updated classification scheme and reproducible diagnostic criteria, based on recent clinicopathologic studies and genetic and molecular data.
Inflammatory leiomyosarcoma: a morphological subgroup within the heterogeneous family of so‐called inflammatory malignant fibrous histiocytoma
TLDR
Evidence is provided that at least one subset of neoplasms, which would have been formerly classified under this rubric, in fact show smooth muscle differentiaton, and many of these tumours were diagnosed initially as inflammatory malignant fibrous histiocytoma.
Superficial CD34-positive fibroblastic tumor: report of 18 cases of a distinctive low-grade mesenchymal neoplasm of intermediate (borderline) malignancy
TLDR
The unique clinicopathological features of superficial CD34-positive fibroblastic tumor define them as a novel subset of low-grade fibroBLastic neoplasms, best considered to be of borderline malignancy.
Activating mutations in the MAP‐kinase pathway define non‐ossifying fibroma of bone
TLDR
This study adds another benign lesion to the spectrum of KRAS‐ and MAP‐kinase signalling‐driven tumours by identifying hotspot KRAS, FGFR1 and NF1 mutations in patients with non‐ossifying fibroma.
Clinicopathologic characteristics of poorly differentiated chordoma
TLDR
Compared to other chordoma subtypes, poorly differentiated chordoma has a significantly decreased mean overall survival after stratification by site, and characteristic SMARCB1 loss and decreased survival compared to conventional/chondroid chordoma.
Non‐ossifying fibroma: A RAS‐MAPK driven benign bone neoplasm†
TLDR
Findings indicate that NOF, for long thought to be reactive, should be considered a true neoplasm, and demonstrate mutations activating the RAS‐MAPK pathway (KRAS, FGFR1 and NF1) in ∼80% of the tumours.
Adamantinoma of long bones. A clinicopathologic study of 85 cases
TLDR
The results indicate that amputation or, when technically feasible, wide en bloc resection is the treatment of choice for adamantinomas of long bones and all patients require long‐term follow‐up for evidence of local recurrence or lung metastasis.
Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases
TLDR
The findings show that CIC-DUX4 sarcomas occur most commonly in young adults within the somatic soft tissues, having a wide spectrum of morphology including round, epithelioid and spindle cells, and associated with an aggressive clinical course, with an inferior overall survival compared with Ewing sarcoma.
Frequent low‐level mutations of protein kinase D2 in angiolipoma
TLDR
It is hypothesize that altered PRKD2 signalling in the adipocytic cells drives tumourigenesis and, in agreement with its pivotal role in angiogenesis, induces the vessel formation that is characteristic for angiolipoma.
Fibrocartilaginous mesenchymoma of bone: a single‐institution experience with molecular investigations and a review of the literature
TLDR
The clinical, radiological and histological features of eight new cases of fibrocartilaginous mesenchymoma collected at a single institution between 1982 and 2016 are described.
...
1
2
3
4
5
...